#USA #San Diego #Fapon Biopharma #AACR #Therapeutic Antibodies

Fapon Biopharma's Participation in AACR Annual Meeting 2026

Fapon Biopharma, a clinical-stage biotechnology company dedicated to the innovation of therapeutic antibodies and fusion proteins, proudly announces its engagement at the AACR Annual Meeting 2026. This important event takes place from April 19 to 22, 2026, in the vibrant city of San Diego, California. Fapon will be stationed at Booth No. 3856 and is set to present four insightful scientific abstracts during the poster sessions, emphasizing their significant advancements in technology and pipeline.

The company plans to underline two principal technology platforms: the IL-10 biased functional engineering and antibody fusion, alongside the VHH human-monkey cross-binding T-cell engagers. These platforms reflect Fapon's commitment to developing innovative treatments aimed at enhancing efficacy and broadening potential applications in immuno-oncology and autoimmune diseases.

At the forefront of their advancements is the IL-10 biased functional engineering and antibody fusion platform, which supports a series of groundbreaking cytokine-based fusion proteins aimed at precise immune modulation. One of their flagship programs is FP008, the world's first in-class PD1 x IL10M fusion protein, which holds promise as a next-generation backbone in cancer immunotherapy. Phase I trial results for FP008 are expected to be available in 2026. Additionally, Fapon is working on FP012, another pioneering TL1A x IL10MM fusion protein, targeted for inflammatory bowel disease and other inflammatory conditions, with IND-enabling CMC/GLP toxicology planned for this year.

Fapon’s proprietary VHH human-monkey cross-binding T-cell engager platform presents an innovative solution to traditional multi-specific antibody challenges, empowering the development of a diverse range of therapeutic candidates. This platform is showcased through their expanding pipeline of CD3/TCR VHHs, including FPE024—anticipated to be a best-in-class CD19xBCMAxCD3 tri-specific T-cell engager for autoimmune diseases, and FPE021, targeting CDH17 with added signaling for gastrointestinal tract cancers. Both of these programs are anticipated to advance into IND-enabling CMC/GLP toxicology in 2026.

Meeting attendees are warmly invited to visit Booth #3856 to explore Fapon Biopharma's evolving research strategies, technological frameworks, and pipeline programs. The company is also on the lookout for strategic partnerships to facilitate co-development and licensing opportunities. Interested parties can reach out to Fapon at their specified contact points for the USA, Europe, and other regions as well as the Asia-Pacific.

Abstract Highlights

• - Abstract #5582: Tri-specific T-cell engager with a second signal enhances response rates, safety and durability against solid tumors. _Presenting on April 21, Section 8, Board 1, from 2:00 PM to 5:00 PM._
• - Abstract #5586: Next-generation CD8-selective tri-specific T-cell engager targeting CDH17, boasting improved efficacy and reduced side effects. _Presenting on April 21, Section 8, Board 5, from 2:00 PM to 5:00 PM._
• - Abstract #1637: A human-cynomolgus cross-reactive CD3 nanobody-centric T-cell engager platform that enhances clinical functionality. _Presenting on April 20, Section 10, Board 29, from 9:00 AM to 12:00 PM._
• - Abstract #5593: A dual-targeting VHH format T-cell engager for CD19/BCMA with a novel CD3 binder for superior potency and safety profile. _Presenting on April 21, Section 8, Board 12, from 2:00 PM to 5:00 PM._

As a leader in the field of biologics, Fapon Biopharma is committed to addressing unmet medical needs through advanced therapeutic approaches. Their extensive drug discovery platforms leverage cutting-edge mammalian cell display technology, aiming to deliver biologics that are safer, more effective, and accessible for all. The company is on a path to build comprehensive drug development processes that encompass everything from discovery to early clinical developments, embodying their mission to advance healthcare innovation.